Mathé G, Schally A V, Comaru-Schally A M, Mauvernay R Y, Vovan M L, Machover D, Misset J L, Court B, Bouchard P, Duchier J
Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):65-74.
In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid phosphatase is therefore considered to be a relatively non-specific tumor marker. A complete remission, i.e. a stage of minimal residual disease, is obtained in about 25% of the patients. Continued endocrine treatment involves the risk of a flare-up of the disease, which is probably small. Additionally, in minimal residual disease, prolonged maintenance treatment requires minimization of side effects. D-Trp-6-LH-RH appears to lead to less gynecomastia and thromboembolism than some other forms of adjuvant therapy.
在显性前列腺癌中，根据不同的标准判断，14% - 44%的患者可实现部分缓解和完全缓解，但根据前列腺酸性磷酸酶的降低情况判断，这一比例可达61%。此外，这种降低与前列腺大小的减小相关性较差。因此，前列腺酸性磷酸酶被认为是一种相对非特异性的肿瘤标志物。约25%的患者可实现完全缓解，即达到最小残留疾病阶段。持续的内分泌治疗存在疾病复发的风险，这种风险可能较小。此外，在最小残留疾病阶段，延长维持治疗需要将副作用降至最低。与其他一些辅助治疗形式相比，D -色氨酸 - 6 - 促黄体生成素释放激素似乎导致的男性乳房发育和血栓栓塞较少。
